Emergent FLT3-ITD Clone at Relapse Following Venetoclax-Based Therapy in NPM1-Mutated Acute Myeloid Leukemia (SOHO 2026) - Sep 1, 2026 - Abstract #AML-1162; "Objective: To describe a case of NPM1-mutated AML with acquisition of FLT3–ITD at relapse following initial MRD-negative remission with azacitidine plus venetoclax...Treatment and Outcome: When FLT3-ITD was identified during a relapse, gilteritinib and venetoclax were used as part of targeted salvage therapy... This case emphasizes the dynamic molecular evolution of NPM1-mutated AML after starting venetoclax-based therapy and highlights the importance of a thorough genomic reevaluation at recurrence. Emergent FLT3-ITD represents a clinically exploitable resistance mechanism, which directly impacts targeted therapy and transplant planning. Early detection of such clonal shifts may optimize sequencing strategies and improve outcomes in relapsed/refractory AML."
Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ANPEP • CD33 • FLT3 • KIT • MPO • NPM1
|
|
Ayesha Nawal MBBS 1; Tooba Nihal MBBS 2; Anid Hassan MD 3; Nuri Tamanna MD 4; Faisal Ansari DO 5; Mifrah Rahat Khan Sherwani MBBS 6; Asad Ullah Farooq MBBS 7
|